Overview
Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.
Eligibility
Inclusion Criteria:
- Adult patients with atopic dermatitis indicated for dupilumab, without current use of oral immunosuppressive treatment .
Exclusion Criteria:
- Treatment with oral or ocular immunosuppressive drugs 2 weeks prior to start of dupilumab treatment